流程图显示SDA BIO疫苗佐剂选择步骤,包括不同产品的推荐与用途,涉及不同类型的乳化液与抗原的混合比例。
图示展示了SDA 1010或SDA 15A的油包水乳液,标明了其成分及特性,包括粒径约100纳米和低粘度特征。
  • 水包油微乳化液 10-20 倍浓缩品,矿物油
  • 可与水性抗原按 1 份油相与 9 份抗原的比例混合。制备活疫苗稀释液可以 1:19
  • 颗粒大小 = ~100 nm
  • 最终乳化液:胶体,略带乳白色
  • 与 10 mg DOTAP 混合,生成 10x CNE(阳离子纳米乳化液)
  • 粘度:<20 mPa.s
Three glass vials labeled 'SDA 1010' containing a white, slightly opaque liquid with bubbles.
Infographic detailing the features of the SDA 4580 vaccine adjuvant, highlighting its emulsion stability matrix, particle size, and immune response enhancement properties.
  • 水包油微乳化液 10-20 倍浓缩品,矿物油
  • 可与水性抗原按 1 份油相与 9 份抗原的比例混合。制备活疫苗稀释液可以 1:19
  • 颗粒大小 = ~80 nm
  • 最终乳化液:胶体,略带乳白色
  • 与 10 mg DOTAP 混合,生成 10x CNE(阳离子纳米乳化液)
  • 粘度:<20 mPa.s
Illustration of SDA 6050 NanoEmulsion Vaccine Adjuvant, depicting its balanced microemulsion structure and properties such as particle size and viscosity.
  • Oil-in-water microemulsion concentrate, mineral oil
  • Ready to combine with aqueous antigen at ratio of 1 part of oil phase to 9 parts of antigen
  • Particle size = ~60 nm
  • Colorless, transparent appearance
  • Mix with 10 mg DOTAP to generate 10x CNE (Cationic Nanoemulsion)
  • Viscosity: <20 mPa.s
Diagram explaining the properties and benefits of SDA 7749 nanoemulsion vaccine adjuvant, detailing its particle size, stability, and use for sensitive animals.
  • 水包油微乳化液 10-20 倍浓缩品,矿物油
  • 可与水性抗原按 1 份油相与 9 份抗原的比例混合。制备活疫苗稀释液可以 1:19
  • 颗粒大小 = ~60 nm
  • 最终乳化液:胶体,略带乳白色
  • 与 10 mg DOTAP 混合,生成 10x CNE(阳离子纳米乳化液)
  • 粘度:<20 mPa.s
五个装有黄色液体的药瓶,瓶盖为蓝色,背景为浅色墙面
SDA BIO Vaccine Adjuvant Selection Map showing a decision tree for selecting the optimal adjuvant based on immunological goals and target species.
A decision tree illustrating the selection process for SDA BIO vaccine adjuvants based on immunological goals, target species, antigen type, recommended adjuvant type, and key considerations.